MATN
$0.19
Mateon Therapeutics
MATN
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Monday
Nov 16
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when MATN reports earnings?
Beat
Meet
Miss

Where is MATN's stock price going from here?
Up
Flat
Down
Stock chart of MATN
Analysts
Summary of analysts' recommendations for MATN
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Mateon Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents for the treatment of cancer. Its product pipeline consists of VDAs-CA4P and OXi4503, which are in preclinical trail stage. Mateon Therapeutics, Inc., formerly known as OXiGENE, Inc., is based in SOUTH SAN FRANCISCO, United States.